Page last updated: 2024-08-25

almagate and Diabetic Retinopathy

almagate has been researched along with Diabetic Retinopathy in 72 studies

Research

Studies (72)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	21 (29.17)	29.6817
2010's	50 (69.44)	24.3611
2020's	1 (1.39)	2.80

Authors

Authors	Studies
Hara, H; Nakamura, S	1
Evans, JR; Gordon, I; Lucenteforte, E; Parravano, M; Virgili, G	2
Duvnjak, L; Ljubić, S; Poljičanin, T; Tomić, M; Vrabec, R	1
Enaida, H; Ishibashi, T; Nakao, S; Yoshida, S	1
Brillante, C; De Paolis, G; Impallara, D; La Torre, G; Malarska, K; Muscella, R; Pacella, E; Pacella, F; Smaldone, G; Turchetti, P	1
García-Campos, JM; López-Gálvez, MI	1
Colby, JA; Ollendorf, DA; Pearson, SD	1
Raczyńska, D; Raczyńska, K; Zorena, K	1
Choovuthayakorn, J; Ittipunkul, N; Kunavisarut, P; Pathanapitoon, K; Patikulsila, D; Saenpen, N; Watanachai, N	1
Badaró, E; Falabella, P; Farah, ME; Koss, M; Maia, M; Stefanini, FR	1
Chong, NV; Morjaria, R	1
Loftus, J; Scanlon, PH; Starita, C; Stratton, IM	1
Takamura, Y	1
Esaka, E; Ishibashi, T; Ishida, S; Isogawa, N; Ohji, M; Yoshimura, N; Yuzawa, M	1
Evans, JR; Menchini, F; Parravano, M; Virgili, G	1
Buil-Calvo, JA; Cordero, JA; Evans, JR; Martí-Carvajal, AJ; Martinez-Zapata, MJ; Pijoán, JI; Solà, I	1
Ehrlich, R; Harris, A; Hussain, RM; Prall, R; Siesky, B; Yung, CW	1
Colucciello, M	1
Barner, JC; Jiang, S; Ling, YL; Park, C	1
Bandello, F; Cicinelli, MV; Parodi, MB	1
Ajlan, RS; Silva, PS; Sun, JK	1
Goverdhan, S; Krishnan, R; Lochhead, J	1
Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A	1
Donati, G; Mendrinos, E; Pournaras, CJ	1
Bhisitkul, RB; Fung, AE	1
Giuliari, GP; Gonzalez, VH; Guel, DA	1
Abdallah, W; Fawzi, AA	1
Do, DV; Khurana, RN; Nguyen, QD	1
Funatsu, H	1
DaCosta, J; Salam, A; Sivaprasad, S	1
Bux, AV; Iaculli, C; Martinelli, D; Noci, ND; Querques, G	1
Banda, RM; Giuliari, GP; González, VH; Guel, DA	1
Menchini, F; Parravano, M; Virgili, G	1
Nicholson, BP; Schachat, AP	1
Edmeades, N; Hornan, D; Khan, J; Krishnan, R; Lochhead, J	1
Cortez, MA; Cortez, RT; Giuliari, GP; Guel, DA	1
Gelisken, F; Ziemssen, F	1
Bandello, F; Battaglia Parodi, M; Iacono, P	1
Joussen, AM; Kakkassery, V; Winterhalter, S	1
Goldstein, M; Loewenstein, A; Waisbourd, M	1
Mathew, R; Salam, A; Sivaprasad, S	1
Correa, ME; Montero, JA; Ruiz-Moreno, JM	1
Kühn, T	1
Dombi, T; Ice, KS; Loftus, J; Sultan, MB; Zhou, D	1
Coney, JM; Hornik, JH; Miller, DG; Schartman, JP	1
Loftus, JV; Pleil, AM; Sultan, MB	1
Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B	1
Huic, M; Zechmeister-Koss, I	1
Bux, AV; Iaculli, C; Noci, ND; Querques, G	1
Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF	1
Fraser-Bell, S; Gillies, M; Salem, W	1
Chiosi, F; Costagliola, C; dell'Omo, R; Mastropasqua, R; Parmeggiani, F; Rinaldi, M; Romano, MR; Semeraro, F	1
Stewart, MW	1
Chong, V	1
Lang, GE	1
O'Malley, PG	1
Bandello, F; Battaglia Parodi, M; Berchicci, L; Iacono, P; La Spina, C	1
Brown, GC; Brown, MM; Ho, AC; Ip, MS; Kim, SJ; Recchia, FM; Scott, IU	1
Brunetti, M; Menchini, F; Parravano, M; Virgili, G	1
Lai, G; Lloyd, AJ; Loftus, J; Pleil, A; Turner, M	1
Huber, S; Kieselbach, GF; Kirchmair, R; Kralinger, MT; Zehetner, C	1
Coster, DJ; van Wijngaarden, P; Williams, KA	1
Adamis, AP; Aiello, LP; Altaweel, M; Bressler, NM; Cunningham, ET; D'Amico, DJ; Goldbaum, M; Guyer, DR; Katz, B; Patel, M; Schwartz, SD	1
Adamis, AP; Altaweel, M; Barrett, K; Bressler, NM; Cunningham, ET; Davis, MD; Goldbaum, M; Gonzales, C; Guyer, DR; Patel, M	1
Adamis, AP; Calias, P; Cunningham, ET; Guyer, DR; Ng, EW; Shima, DT	1
Ducharme, JF; Filippopoulos, T; Krzystolik, MG; Loewenstein, JI	1
Adamis, AP; Katz, B; Patel, M; Starita, C	1
Bansal, AG; Majji, AB; Narayanan, R; Thomas, R	1
Joussen, AM	1
Hernández, C; Simó, R	1
Cervera, E; Diaz-Llopis, M; Garcia-Delpech, S; Udaondo, P	1

Reviews

40 review(s) available for almagate and Diabetic Retinopathy

Article	Year
[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2021, Volume: 141, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Drug Development; Humans; Macular Degeneration; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A	2021
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. The Cochrane database of systematic reviews, 2017, 06-22, Volume: 6 Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity	2017
Diabetic Macular Edema: Traditional and Novel Treatment Acta clinica Croatica, 2017, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Dexamethasone; Diabetic Retinopathy; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Practice Guidelines as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy	2017
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. The Cochrane database of systematic reviews, 2018, 10-16, Volume: 10 Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity	2018
[From scientific evidence to clinical practice: treatment protocols for diabetic macular edema]. Archivos de la Sociedad Espanola de Oftalmologia, 2012, Volume: 87 Suppl 1 Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Protocols; Diabetic Retinopathy; Drug Approval; European Union; Fluorescein Angiography; Humans; Laser Coagulation; Macular Edema; Microscopy, Acoustic; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tomography, Optical Coherence; Translational Research, Biomedical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A	2012
Comparative effectiveness of anti-VEGF agents for diabetic macular edema. International journal of technology assessment in health care, 2013, Volume: 29, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Comparative Effectiveness Research; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2013
Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators of inflammation, 2013, Volume: 2013 Topics: Adalimumab; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Aptamers, Nucleotide; Bevacizumab; Biomarkers; Diabetic Retinopathy; Etanercept; Eye Proteins; Humans; Immunoglobulin G; Infliximab; Interleukin-12; Mice; Neovascularization, Pathologic; Nerve Growth Factors; Quality of Life; Ranibizumab; Receptors, Tumor Necrosis Factor; Rituximab; Serpins; Somatomedins; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2013
Anti-VEGF for the management of diabetic macular edema. Journal of immunology research, 2014, Volume: 2014 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Trials as Topic; Diabetic Retinopathy; Gene Expression; Humans; Intravitreal Injections; Light Coagulation; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2014
Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:8 Topics: Animals; Aptamers, Nucleotide; Cardiovascular Diseases; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Risk Factors; Vascular Endothelial Growth Factor A; Vision Disorders	2014
Anti-vascular endothelial growth factor for diabetic macular oedema. The Cochrane database of systematic reviews, 2014, Oct-24, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Triamcinolone; Vascular Endothelial Growth Factor A	2014
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. The Cochrane database of systematic reviews, 2014, Nov-24, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Female; Humans; Light Coagulation; Male; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative	2014
Current intravitreal pharmacologic therapies for diabetic macular edema. Postgraduate medicine, 2015, Volume: 127, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Ranibizumab	2015
Anti-VEGF Molecules for the Management of Diabetic Macular Edema. Current pharmaceutical design, 2015, Volume: 21, Issue:32 Topics: Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity	2015
Vascular Endothelial Growth Factor and Diabetic Retinal Disease. Seminars in ophthalmology, 2016, Volume: 31, Issue:1-2 Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Edema; Ranibizumab; Vascular Endothelial Growth Factor A	2016
Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema. Current diabetes reviews, 2009, Volume: 5, Issue:1 Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Fluorescein Angiography; Humans; Macular Edema; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A	2009
Anti-VEGF therapy in proliferative diabetic retinopathy. International ophthalmology clinics, 2009,Spring, Volume: 49, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreoretinopathy, Proliferative; Vitreous Body	2009
[Progress in therapy for and diagnosis of diabetic complications--diabetic retinopathies]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Drug Design; Humans; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2009
Anti-vascular endothelial growth factor agents for diabetic maculopathy. The British journal of ophthalmology, 2010, Volume: 94, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Evidence-Based Medicine; Humans; Macular Edema; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Randomized Controlled Trials as Topic; Triamcinolone; Vascular Endothelial Growth Factor A	2009
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2010, Volume: 248, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Trials as Topic; Diabetic Retinopathy; Humans; Ranibizumab; Vascular Endothelial Growth Factor A	2010
Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2010, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Retinal Neovascularization; Vascular Endothelial Growth Factor A	2010
[Diabetic maculopathy. Diagnosis and treatment]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2010, Volume: 107, Issue:8 Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Glycated Hemoglobin; Humans; Intravitreal Injections; Ischemia; Laser Coagulation; Macular Edema; Ophthalmoscopy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A	2010
[Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema]. Klinische Monatsblatter fur Augenheilkunde, 2010, Volume: 227, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Capillary Permeability; Clinical Trials as Topic; Combined Modality Therapy; Diabetic Retinopathy; Fluorescein Angiography; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Middle Aged; Off-Label Use; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinoscopy; Triamcinolone; Vascular Endothelial Growth Factor A	2010
Treatment of diabetic retinopathy with anti-VEGF drugs. Acta ophthalmologica, 2011, Volume: 89, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy	2011
Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta ophthalmologica, 2011, Volume: 89, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Ranibizumab; Vascular Endothelial Growth Factor A	2011
Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery. Current diabetes reviews, 2011, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Chemotherapy, Adjuvant; Combined Modality Therapy; Diabetic Retinopathy; Humans; Intravitreal Injections; Ranibizumab; Vascular Endothelial Growth Factor A; Vitrectomy	2011
Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. The British journal of ophthalmology, 2012, Volume: 96, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Retreatment; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity	2012
Clinical development of new treatments for diabetic macular oedema. Clinical & experimental optometry, 2012, Volume: 95, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract Extraction; Dexamethasone; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Pregnadienetriols; Tomography, Optical Coherence; Triamcinolone Acetonide	2012
Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Current diabetes reviews, 2012, Jul-01, Volume: 8, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Capillary Permeability; Cell Proliferation; Diabetic Retinopathy; Endothelial Cells; Female; Humans; Hyperglycemia; Intravitreal Injections; Macular Edema; Male; Oxidative Stress; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factors	2012
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2012, Volume: 227 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2012
Diabetic macular edema. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2012, Volume: 227 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2012
Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions. Archives of internal medicine, 2012, Jul-09, Volume: 172, Issue:13 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Comparative Effectiveness Research; Diabetic Retinopathy; Drug Costs; Evidence-Based Medicine; Humans; Intravitreal Injections; Macular Edema; Off-Label Use; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; United States; Vascular Endothelial Growth Factor A	2012
Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic research, 2012, Volume: 48 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2012
Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology, 2012, Volume: 119, Issue:10 Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Edema; Ophthalmology; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Technology Assessment, Biomedical; Treatment Outcome; United States; Vascular Endothelial Growth Factor A	2012
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Laser Coagulation; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Triamcinolone; Vascular Endothelial Growth Factor A	2012
Inhibitors of ocular neovascularization: promises and potential problems. JAMA, 2005, Mar-23, Volume: 293, Issue:12 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Injections; Macular Degeneration; Oligonucleotides; Ranibizumab; Vascular Endothelial Growth Factor A	2005
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature reviews. Drug discovery, 2006, Volume: 5, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Drug Delivery Systems; Eye; Eye Diseases; Humans; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A	2006
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Developments in ophthalmology, 2007, Volume: 39 Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Blood-Retinal Barrier; Diabetic Retinopathy; Humans; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity	2007
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]. Deutsche medizinische Wochenschrift (1946), 2007, Jun-08, Volume: 132, Issue:23 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases	2007
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia, 2008, Volume: 51, Issue:9 Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Diabetic Retinopathy; Humans; Hypertension; Proteinuria; Vascular Endothelial Growth Factor A	2008

Trials

7 trial(s) available for almagate and Diabetic Retinopathy

Article	Year
[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]. Nippon Ganka Gakkai zasshi, 2014, Volume: 118, Issue:9 Topics: Aged; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Intravitreal Injections; Macular Edema; Male; Treatment Outcome	2014
Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. The British journal of ophthalmology, 2009, Volume: 93, Issue:11 Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Injections, Intralesional; Laser Coagulation; Male; Middle Aged; Pilot Projects; Prospective Studies; Retinal Neovascularization	2009
A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology, 2011, Volume: 118, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Fundus Oculi; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Male; Middle Aged; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Young Adult	2011
Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Investigative ophthalmology & visual science, 2011, Sep-29, Volume: 52, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Macular Edema; Male; Middle Aged; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Tomography, Optical Coherence; Treatment Outcome; Vision, Ocular; Visual Acuity; Young Adult	2011
Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health and quality of life outcomes, 2013, Jan-24, Volume: 11 Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Interviews as Topic; Macular Edema; Male; Middle Aged; Psychometrics; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Vision, Ocular; Young Adult	2013
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. The British journal of ophthalmology, 2013, Volume: 97, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intravitreal Injections; Macular Edema; Male; Postoperative Period; Preoperative Period; Prospective Studies; Ranibizumab; Vascular Endothelial Growth Factor A; Wet Macular Degeneration	2013
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 2005, Volume: 112, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Injections; Macular Edema; Male; Middle Aged; Oligonucleotides; Safety; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body	2005

Other Studies

25 other study(ies) available for almagate and Diabetic Retinopathy

Article	Year
[Molecular targeting therapy for diabetic retinopathy]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Molecular Targeted Therapy; Ranibizumab; Vascular Endothelial Growth Factor A	2012
Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up. La Clinica terapeutica, 2013, Volume: 164, Issue:2 Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Time Factors; Treatment Outcome	2013
The use of intravitreal anti-vascular endothelial growth factor injection and its complications in Chiang Mai University Hospital. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Child; Child, Preschool; Diabetic Retinopathy; Female; Hospitals, University; Humans; Infant; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Thailand; Vascular Endothelial Growth Factor A; Young Adult	2013
The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:1 Topics: Aged; Aptamers, Nucleotide; Cross-Sectional Studies; Diabetic Retinopathy; Female; Humans; Macular Edema; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Visual Acuity	2015
[Anti-VEGF therapy to treat diabetic macular edema]. Nippon Ganka Gakkai zasshi, 2014, Volume: 118, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A	2014
The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases. Acta ophthalmologica, 2015, Volume: 93, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Flow Velocity; Diabetic Retinopathy; Female; Humans; Injections, Intraocular; Ischemia; Laser-Doppler Flowmetry; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Artery; Retinal Vein Occlusion; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A	2015
Treatment Patterns of Anti-Vascular Endothelial Growth Factor and Laser Therapy Among Patients with Diabetic Macular Edema. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:9 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Cohort Studies; Diabetic Retinopathy; Female; Humans; Laser Therapy; Logistic Models; Macular Edema; Male; Middle Aged; Ranibizumab; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult	2015
Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye (London, England), 2009, Volume: 23, Issue:5 Topics: Adult; Aptamers, Nucleotide; Diabetic Retinopathy; Disease Progression; Female; Humans; Intravitreal Injections; Middle Aged; Retinal Detachment; Visual Acuity	2009
[Intravitreous injection: retrospective study on 2028 injections and their side effects]. Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage	2008
Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta ophthalmologica, 2009, Volume: 87, Issue:6 Topics: Adult; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Neovascularization, Pathologic; Optic Disk; Remission Induction; Severity of Illness Index; Vascular Endothelial Growth Factor A	2009
Safety monitoring with ocular anti-vascular endothelial growth factor therapies. The British journal of ophthalmology, 2008, Volume: 92, Issue:12 Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Vascular Endothelial Growth Factors	2008
Anti-VEGF therapeutic approaches for diabetic macular edema. International ophthalmology clinics, 2009,Spring, Volume: 49, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Disease Models, Animal; Humans; Injections; Macular Edema; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreous Body	2009
Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta ophthalmologica, 2009, Volume: 87, Issue:6 Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Eyeglasses; Female; Follow-Up Studies; Fovea Centralis; Humans; Injections; Macula Lutea; Macular Edema; Male; Middle Aged; Photoreceptor Cells, Vertebrate; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body	2009
Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. Eye (London, England), 2010, Volume: 24, Issue:8 Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Intravitreal Injections; Male; Middle Aged; Preoperative Care; Prospective Studies; Recurrence; Visual Acuity; Vitreous Hemorrhage	2010
Antivascular endothelial growth factor in diabetic retinopathy. Developments in ophthalmology, 2010, Volume: 46 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Edema; Ranibizumab; RNA, Small Interfering; Sirolimus; Vascular Endothelial Growth Factor A	2010
[Results of an expert survey on VEGF inhibitors in ophthalmology]. Klinische Monatsblatter fur Augenheilkunde, 2011, Volume: 228, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Data Collection; Diabetic Retinopathy; Germany; Humans; Interviews as Topic; Intravitreal Injections; Macular Degeneration; Ophthalmology; Practice Patterns, Physicians'; Ranibizumab; Vascular Endothelial Growth Factor A	2011
Pegaptanib octasodium for the treatment of diabetic macular edema. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8 Topics: Aptamers, Nucleotide; Clinical Trials, Phase II as Topic; Diabetic Retinopathy; Humans; Macular Edema; Vascular Endothelial Growth Factor A	2011
[Complications of intravitreal injections--own experience]. Klinika oczna, 2011, Volume: 113, Issue:4-6 Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity	2011
Lamellar macular hole following intravitreal pegaptanib sodium (Macugen) injection for diabetic macular edema. International ophthalmology, 2011, Volume: 31, Issue:6 Topics: Aged; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Humans; Intravitreal Injections; Macular Edema; Retinal Perforations; Vascular Endothelial Growth Factor A	2011
[Intravitreal injections: AFSSAPS guide to good practice]. Journal francais d'ophtalmologie, 2012, Volume: 35, Issue:1 Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical	2012
Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. British journal of clinical pharmacology, 2012, Volume: 74, Issue:6 Topics: Aged; Aptamers, Nucleotide; Color Perception; Color Perception Tests; Diabetic Retinopathy; Female; Fovea Centralis; Humans; Intravitreal Injections; Longitudinal Studies; Macular Edema; Male; Middle Aged; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity	2012
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology, 2006, Volume: 113, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Fluorescein Angiography; Humans; Injections; Macular Edema; Male; Middle Aged; Randomized Controlled Trials as Topic; Retinal Neovascularization; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body	2006
Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:6 Topics: Aptamers, Nucleotide; Chemotherapy, Adjuvant; Diabetic Retinopathy; Glaucoma Drainage Implants; Glaucoma, Neovascular; Gonioscopy; Humans; Injections; Iris; Lens Implantation, Intraocular; Male; Middle Aged; Neovascularization, Pathologic; Phacoemulsification; Postoperative Complications; Vitrectomy	2006
Neovascular changes after pegaptanib in diabetics. Ophthalmology, 2007, Volume: 114, Issue:3 Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Randomized Controlled Trials as Topic; Retinal Neovascularization; Vascular Endothelial Growth Factor A	2007
Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema. Eye (London, England), 2008, Volume: 22, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Diabetic Retinopathy; Female; Fluorescein Angiography; Humans; Macular Edema; Male; Middle Aged; Prospective Studies; Pseudophakia; Tomography, Optical Coherence; Treatment Outcome; Vitrectomy	2008